Agilent Lung Cancer Companion Diagnostic Approved in China
October 02 2019 - 11:32AM
Dow Jones News
By Michael Dabaie
Agilent Technologies Inc. (A) said China's National Medical
Products Administration approved its PD-L1 IHC 22C3 pharmDx assay
for use in China.
The assay is now approved as a companion diagnostic to identify
patients with locally advanced or metastatic non-small cell lung
cancer whose tumors express PD-L1 for first-line treatment with
single-agent Keytruda, which is made by Merck & Co. Inc. (MRK),
Agilent said.
"Pathologists in China recognize the need for validated tests,
and our companion diagnostic gives them a highly accurate tool to
inform oncologists on PD-L1 expression for metastatic NSCLC
patients," said Sam Raha, president of Agilent's Diagnostics and
Genomics Group.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 02, 2019 11:17 ET (15:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024
